Mumbai, 15 November 2016 – MedGenome, a genomics-driven research and diagnostics company, organised a continuous medical education session in association with Aasha Cancer Hospital, Mumbai. This event was attended by 100 of the city’s leading consultants and specialists from the field of obstetrics, gynaecology, and general surgery to name a few along with patients.
The topic of the event was “Inherited risk for breast & ovarian cancer”. MedGenome’s scientific affairs team spoke about the risk of inheriting breast and ovarian cancer, the importance of genetic testing to identify an individual for breast/ovarian cancer risk, testing for BRCA1/2 gene mutation analysis, benefits and limitations of genetic testing and screening and cancer management for an individual who has a BRCA1/2 gene mutation.
Dr Satish Kamat, Cancer specialist & Surgeon, who attended the conference said, “Genetic testing is the future of the diagnostic industry. It provides us genomic information which helps in managing health care. MedGenome is the only lab having the advanced facilities to perform genetic tests.”
About MedGenome:
MedGenome is a genomics-driven research and diagnostics company with a mission to improve global health by decoding the genetic information contained in an individual’s genome. MedGenome is a market leader for genomic diagnostics in South Asia and a leading provider of genomics research services globally. MedGenome offers genomics solutions in cancer immunotherapy and diabetes and works with various commercial and academic researchers globally on genomic research projects. It is also a founding member of GenomeAsia 100K initiative to sequence 100,000 genomes in South, North and East Asia.
MedGenome is a global genomics firm with presence in USA, India and Singapore. Our NGS lab in Foster City, California is ISO 15189 compliant, CLIA certified and CAP accredited. Our NGS lab in Bangalore, India is the highest throughput facility in South-East Asia.